kras-g12c

Skip to content The CRC Digest ▸ TREATMENT Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRC A phase 1b/2 trial found that ifebemtinib plus garsorasib demonstrated anticancer activity and manageable safety in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer, though the improvement in response rate did not

Skip to content The CRC Digest ▸ TREATMENT Combination therapy targets KRAS G12C mutation in metastatic CRC The Lancet Oncology published results showing encouraging antitumor activity of ifebemtinib combined with garsorasib in previously treated patients whose metastatic colorectal cancer harbors the KRAS G12C mutation. (The Manila Times) This content is informational

Skip to content The CRC Digest ▸ TREATMENT Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancer A combination of ifebemtinib and garsorasib demonstrated encouraging antitumor activity in previously treated metastatic colorectal cancer patients with KRAS G12C mutations, according to results published in The Lancet Oncology. (The Manila

Skip to content The CRC Digest ◆ TRIAL DATA Ifebemtinib plus garsorasib shows activity in KRAS G12C-mutated metastatic colorectal cancer A phase 1b/2 trial tested the combination of ifebemtinib (a focal adhesion kinase inhibitor) with garsorasib (a KRAS G12C inhibitor) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer.